NASHVILLE, Tenn. -- Racial biases persist in the use of pulse oximetry devices for patients with acute hypoxemic respiratory failure (AHRF) requiring very high levels of oxygen support, a ...

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

Abstract: The paper proposes the diagnosis of Sleep Apnea Hypopnea Syndrome (SAHS) only using snore sound and SaO2 signals. The time-frequency characteristics of snore sound signal are extracted to ...

Cytokinetics, Incorporated's (CYTK) shares surged 40.4% on Sept. 2, driven by positive results from a phase III study on cardiovascular candidate aficamten. On Aug. 30, Cytokinetics presented primary ...

Data from the late-stage MAPLE-HCM study position Cytokinetics’ cardiac myosin inhibitor aficamten as a potential first-line therapy for patients with obstructive hypertrophic cardiomyopathy.

During a medical event on Saturday, Cytokinetics (NASDAQ:CYTK) announced primary results from its Phase 3 MAPLE-HCM trial for lead asset aficamten in symptomatic obstructive hypertrophic ...

Serious hidden hypoxemia — defined as an SaO2 less than 88% despite an SpO2 of 92% or greater — occurred in 0.6% of the critically ill Asian patients studied. Hypoxemia went undetected in 0.8% of ...

(RTTNews) - Cytokinetics, Incorporated (CYTK), Tuesday announced positive topline results from Phase 3 MAPLE-HCM study of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy ...

Trial Demonstrates Superiority of Aficamten to Standard of Care Beta Blocker in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy The full results from ...

The U.S. Food and Drug Administration (FDA) on Thursday extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for Cytokinetics Inc's (NASDAQ:CYTK) ...